

Review**Early onset adiposity: A pathway to polycystic ovary syndrome in adolescents?**

Evanthia Diamanti-Kandarakis, Charikleia D. Christakou, Eleni Kandaraki, Krystallenia I. Alexandraki

First Department of Medicine, Endocrine Section, Athens University School of Medicine, Athens, Greece

ABSTRACT

Polycystic Ovary Syndrome is a heterogenous syndrome of unknown causation commonly associated with obesity. The particular timing of the onset of obesity may be important, since the earlier the onset of obesity the greater the severity of the metabolic and hormonal aberrations. Early postnatal life and peripubertal periods may be critical windows for the development of the “adiposity insult”. The interaction of adiposity with genetic traits as well as with prenatal environmental factors may further aggravate the metabolic and endocrine abnormalities, which become more pronounced in adolescence.

Key words: Adolescence, Intrauterine growth retardation, Obesity, PCOS, Visceral adiposity

INTRODUCTION

Polycystic Ovary Syndrome (PCOS), the most common endocrine disorder of women of reproductive age,¹ is characterized by chronic anovulation and clinical or biochemical hyperandrogenemia.² The pathogenesis of PCOS remains largely unknown. Ongoing research points to a multifactorial pathophysiologic model³ interweaving genetic⁴ and environmental/nutritional factors.⁵ Recently, the ESHRE/ASRM Consensus⁶ has introduced new phenotypes of PCOS requiring two of the following features for the diagnosis of PCOS: chronic anovula-

tion, biochemical and/or clinical hyperandrogenemia and distinct sonographic appearance of the ovaries. The actual clinical significance of these phenotypes is controversial⁷ and the AES position statement did not declare the inclusion of anovulatory non-hyperandrogenic women with ultrasonographic polycystic ovarian morphology in the PCOS cohort.⁷ Although not included in the definition of PCOS, research has placed particular emphasis on the pivotal pathogenetic role of adiposity in PCOS. Relevant literature has eloquently suggested that adiposity and the attendant insulin resistance (IR) can significantly contribute to hormonal aberrations^{8,9} and amplify the metabolic¹⁰⁻¹³ and cardiovascular risk,¹⁴⁻¹⁶ which may be inherently increased in PCOS. The detrimental consequences of adiposity appear to originate from its clinical emergence onwards and may already be present in adolescence.¹⁷ Given the alarming spread of the

Address for correspondence:

Evanthia Diamanti-Kandarakis, MD, University of Athens Medical School, 1A Zefyrou Str., Ekali 175 62, Athens, Greece, Tel: +30 210 8133318, Fax: +30 210 8130031, E-mail: akandara@otenet.gr

Received 17-01-07, Revised 03-04-07, Accepted 05-05-07

“obesity epidemic” in childhood and adolescence,¹⁸ this review attempts to provide insights into the role of early adiposity in the pathogenesis of PCOS in adolescents.

Obesity in childhood and adolescence is intimately linked with IR²⁸ and has emerged as a significant initiator of early onset Metabolic Syndrome.¹⁸ Visceral adiposity appears to be of major pathophysiologic relevance to insulin resistance and Metabolic Syndrome.^{29,30} Pertinent studies have shown that IR is associated with increased prevalence of MBS among overweight or obese Hispanic adolescents,^{31,32} pointing to the key role played by obesity and obesity-related IR in the pathogenesis of the MBS.³⁰

Visceral adiposity is the commonest phenotype of PCOS, present in 50–70% of adult patients,^{17,33} and the same appears to hold true among adolescents with hyperandrogenemia.²⁵ This devastating incidence has prompted investigators to explore the pathophysiologic implications of obesity in the pathogenesis or clinical emergence of PCOS.

Peripubertal obesity has been incriminated for peripubertal hyperandrogenemia and the consequent endocrine/reproductive disturbances in adult women.^{34,35} In the study by Mc Cartney et al, overweight girls (defined as BMI-for-age ≥ 95 th percentile) presented with significant hyperandrogenemia compared to their normal-weight peers,³⁴ findings indicating that obesity plays an inciting role in the early development of androgen excess, which may precipitate PCOS.

The well recognized role of adipose tissue as an additional site of testosterone formation from circulating precursors may account in part for the adverse effects of adiposity on the hormonal profile.^{36,37}

Additionally, obesity is intimately linked with insulin resistance and compensatory hyperinsulinemia and the latter is postulated to have a multifactorial impact on the ovarian function. Hyperinsulinemia may directly stimulate ovarian theca cell androgen synthesis^{38,39} and synergise with LH in premature follicular luteinization. Hyperinsulinemia also suppresses hepatic production of SHBG, further increasing the unbound testosterone concentrations.³⁸ By contrast, weight loss^{40,41} and pharmaceutical modalities that

ameliorate hyperinsulinemia were shown to be beneficial to the alleviation of hyperandrogenemia and ovulatory dysfunction in these individuals.^{42,43,91}

Hyperandrogenemia of peripubertal obesity may aggravate the PCOS phenotype in a dual mode. In adult women with PCOS⁴⁴ and in hyperandrogenemic adolescents,⁴⁵⁻⁴⁸ androgen excess has been associated with persistently increased GnRH pulse frequency, which has been attributed to the androgen-induced resistance of the GnRH pulse generator to negative progesterone feedback.⁴⁹⁻⁵² This abnormality could result in unduly elevated LH secretion, which may perpetuate ovarian androgen production and ovulatory dysfunction, contributing to the adult PCOS phenotype.

Additionally, peripubertal hyperandrogenemia in conjunction with obesity may precipitate significant metabolic aberrations emerging in such an early stage and lasting throughout the individual’s lifetime. The postulated relationship between adiposity and androgen excess appears to be bidirectional. Early adiposity promotes hyperandrogenemia, and conversely androgen excess may conspire to central adiposity and PCOS related metabolic aberrations (Figure 1).^{35,53} Hyperandrogenemia may impose an independent burden of metabolic derangement which adds to the




Figure 1. Early onset of obesity and hyperinsulinemia effect on peripubertal hyperandrogenemia.

obesity related metabolic risk. Specifically, hyperandrogenemia appears to contribute to the characteristic body fat distribution linked with IR and MBS.⁵³ The validity of this concept was initially shown in adult patients and presumably also applies to adolescent girls with PCOS (or hyperandrogenemia).

Recent retrospective studies in adult women with PCOS have suggested that the prevalence of MBS is twice that of the general population independently of Body Mass Index^{54,55} and adolescents with PCOS are reasonably considered to run a proportionally heightened risk for metabolic aberrations⁵⁶⁻⁵⁸ or the full-blown Metabolic Syndrome.²⁵

The study by Coviello et al²⁵ provided strong evidence that adolescents with PCOS have an increased prevalence of MBS and pointed to hyperandrogenemia as a risk factor for MBS, independently of obesity and IR.

Corroborating data have been derived from studies among PCOS subjects showing the beneficial metabolic effect elicited by antiandrogen therapy. Flutamide, a non-steroidal antiandrogen, has been shown to decrease the central fat mass when assigned as monotherapy in obese and non-obese adult patients⁵⁹ as well as when co-administered with metformin in adolescents with PCOS.^{60,61} Ibanez et al have also provided evidence of an additive effect on the improvement of body composition, androgen levels, lipid levels and IR when metformin and flutamide were combined⁶¹, probably reflecting an interwoven circuit between hyperandrogenemia, hyperinsulinemia and obesity in the pathogenesis of the PCOS.

The putative contribution of androgen excess to the development of the MBS (the metabolic component/equivalent of PCOS) is further supported by the identification of androgen receptors (ARs) on preadipocytes and adipocytes. The AR expression is significantly more pronounced in the visceral vs the subcutaneous fat, suggesting the preferential visceral fat accumulation in the setting of hyperandrogenemia.⁶²

Moreover, adipose tissue is a known source of proinflammatory cytokines such as TNF- α , IL-6 and plasminogen activator inhibitor, which have been found to be increased in individuals with MBS.⁶³

Thus, hyperandrogenemia may exert adverse effects on adipose tissue metabolism by modifying the production or action of cytokines.³⁵

The above presented model reconciles existing data on the role of early adiposity in the development of metabolic and hormonal aberrations of PCOS. Adiposity of childhood and adolescence appear to superimpose an additional risk upon an inherent predisposition rather than being a primary determinant. This putative inherent proneness may be conferred both by genetic traits^{4,64-66} and by environmental cues acting from fetal life onwards.^{5,65,67} The developmental cascade interweaves several interacting factors with each other to orchestrate the final outcome, namely the hormonal and reproductive aspects of PCOS. In light of this, early adiposity has been suggested as contributing to peripubertal hyperandrogenemia, which may act as a trigger of reprogramming adaptations of the hypothalamic-pituitary axis.³⁵

We will further discuss the relevance of low birth weight and early catch-up growth on the model of early adiposity and the implications for the development of PCOS.

A putative developmental program linking low birth weight (LBW) and early catch-up weight gain with hyperandrogenemia in early adolescence and the metabolic and hormonal stigmata of PCOS in late adolescence and adulthood has been suggested. This process has also been associated with the propensity to develop several components of MBS, such as central obesity, IR and impaired glucose tolerance.⁶⁸⁻⁷⁰

Early weight gain appears to be a “key player” in the putative chain of causality between LBW and metabolic/endocrine derangements. The exact timing of the catch-up of weight, which may be of significant relevance to the adiposity-related impact, continues to be debated.⁷¹ Several contemporary birth cohort studies have shown that early infant weight gain is positively associated with subsequent obesity risks.^{72,73} In 1-year old infants who were born small for gestational age (SGA) and experienced a rapid catch-up of weight,⁷⁴ insulin sensitivity was found to be reduced with a trend for further aggravation.^{75,76}

Other studies of adults with cardiovascular disease and Type 2 Diabetes have demonstrated that

weight gain during early childhood, but after infancy, contributes to persistent obesity in adulthood.^{77,78} In another study, both infancy and early childhood body weights contributed independently to increased body fat mass at age 17 years.⁷⁹

However, the first study to report longitudinal data on the development of total and central body fat mass and the metabolic parameters in SGA children with spontaneous postnatal catch-up weight gain was performed by Ibanez et al.⁷⁹ In this study, SGA children were shown to gain more body fat and abdominal fat mass than appropriate for gestational age (AGA) children, along with a change from insulin sensitivity to insulin resistance between ages 2 to 4 years. These striking differences occurred despite comparable BMI values in SGA and AGA children. Moreover, in 4-year old children, total and abdominal fat mass were shown to correlate with weight gain in the age range of 0-2 years, pointing to the major role of early postnatal increments of weight in precipitating future obesity.⁷⁹

In this context, insulin resistance has emerged as the core abnormality.⁷⁹ A mechanism of muscle specific IR has been purported to operate in SGA infants with early catch-up growth and lead to lesser gains in lean mass and the diversion of nutrients toward fat accumulation.⁸⁰ The accumulation of visceral fat may lead to insulin resistance, by increasing the release of FFAs, while the early development of hyperinsulinemia could provide positive feedback to promote peripheral and central fat deposition.

Beyond the metabolic defects mimicking the PCOS metabolic component, low birth weight has also been associated with the endocrine aberrations of PCOS.⁸¹⁻⁸⁸

SGA infants with early catch-up growth have shown a predisposition to premature adrenarche, a potential forerunner of ovarian hyperandrogenism in adolescence and adulthood.⁸¹ Longitudinal and cross-sectional studies have shown that girls with premature pubarche and a history of low birth weight (LBW-PP girls) are at risk for early menarche and further progression to hyperinsulinemic hyperandrogenism and anovulation.⁸¹⁻⁸⁸

Furthermore, premature androgen excess may

represent an additional mechanism, besides early insulin resistance, that contributes to the elevated metabolic risk of individuals with a history of low birth weight. Girls with a history of LBW have been tentatively identified as showing a cluster of cardiovascular risk factors at the age of 8 years.^{82,83}

Insulin resistance and hyperinsulinemia may be the key mechanism underlying this perpetual sequence of hormonal and metabolic aberrations. This sequence may commence early in life and extend throughout life (Figure 2). An attempt to optimize the outcome of girls at risk for PCOS by reversing their metabolic abnormalities has been undertaken by Ibanez et al. The investigators have administered metformin in pre- or peripubertal hyperandrogenic girls with a history of low birth weight and premature pubarche and have found significant improvement across a wide array of hormonal and metabolic abnormalities.⁸⁹⁻⁹² The attenuation of hyperandrogenemia and menstrual disturbances that was accomplished in concert with the improvement of insulin sensitivity has attested to the causal role of insulin resistance in this pathogenic circuit.

On the whole, rapid postnatal weight gain and adiposity appear to dominate over the initial prenatal triggering event, namely fetal growth restriction and low birth weight. It could be suggested that the initial impact of a triggering event might be relatively subtle and the permanent reflections of this event may be magnified by environmental insults through




Figure 2. The hypothetical natural course of PCOS from birth to adulthood.

time. In the particular context of low birth weight and early catch-up, the mismatch between prenatal and postnatal environment may create a favourable ground for metabolic and endocrine aberrations to develop. Sustaining the ideal body weight in the postnatal period and throughout the life cycle could counterbalance the predisposition of individuals with LBW to the aforementioned morbidities.

CONCLUSIONS

Early female adiposity is increasingly recognized as a critical cue for the development or the aggravation of clinical manifestations of PCOS. This has highlighted the prime importance of timely intervention in the clinical course of obesity to minimize the associated hormonal and metabolic aberrations. However, not all obese/overweight adolescents share a similar risk for developing these abnormalities. Genetic predisposition, duration of obesity, presence of other adverse factors from the medical history (like the history of low birth weight) are major determinants of risk for PCOS and the associated hormonal and metabolic abnormalities. The appropriate risk stratification for adolescents could guide clinicians in recognizing overweight youth who are at higher risk and thereby lead to a prompt intervention before consequences become apparent and probably irreversible.

REFERENCES

1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al, 1999 A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. *J Clin Endocrinol Metab* 84: 4006-4011.
2. Zawadzki JK, Dunaif A 1992 Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In: *Polycystic Ovary Syndrome*, Dunaif, A, Givens, JR, Haseltine, FP, Merriam, GE (Eds), (Series Ed: Hershman, SM), Current Issues in Endocrinology and Metabolism, Blackwell Scientific Publications, Boston; p, 377.
3. Diamanti-Kandarakis E, Papavassiliou AG, 2006 Molecular mechanisms of insulin resistance in polycystic ovary syndrome. *Trends Mol Med* 12: 324-332.
4. Diamanti-Kandarakis E, Piperi C, 2005 Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. *Hum Reprod Update* 11: 631-643.
5. Diamanti-Kandarakis E, Piperi C, Spina J, et al, 2006 Polycystic ovary syndrome: the influence of environmental and genetic factors. *Hormones (Athens)* 5: 17-34.
6. The Rotterdam ESHRE/ ASRM-sponsored PCOS Consensus Workshop Group, 2004 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertil Steril* 81: 19-25.
7. Azziz R, Carmina E, Dewailly D, et al, 2006 Position Statement: Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline. *J Clin Endocrinol Metab* 91: 4237-4245.
8. Ehrmann DA, 2005 Polycystic ovary syndrome. *N Engl J Med* 352: 1223-1236.
9. Dunaif A, 1997 Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. *Endocr Rev* 18: 774-800.
10. Diamanti-Kandarakis E, Christakou C, Kandarakis H, 2007 Polycystic Ovarian Syndrome: The commonest cause of hyperandrogenemia in women as a risk factor for Metabolic Syndrome. *Minerva Endocrinol* 32: 35-47.
11. Kousta E, Tolis G, Franks S, 2005 Polycystic ovary syndrome. Revised diagnostic criteria and long-term health consequences. *Hormones (Athens)* 4: 133-147.
12. Legro RS, Kusanman AR, Dunaif A, 2001 Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. *Am J Med* 111: 607-611.
13. Diamanti-Kandarakis E, Piperi C, Kalofoutis A, Creasas G, 2005 Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. *Clin Endocrinol (Oxf)* 62: 37-43.
14. Guzick D, Editorial: Cardiovascular risk in PCOS *J Clin Endocrinol Metab* 89: 3694-3695.
15. Diamanti-Kandarakis E, Palioniko G, Alexandraki K, Bergiele A, Koutsouba T, Bartzis M, 2004 The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. *Eur J Endocrinol* 150: 793-798.
16. Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I, 2001 Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. *J Clin Endocrinol Metab* 86: 4666-4673.
17. Silfen M, Denburg M, Manibo A, et al, 2003 Early Endocrine, Metabolic, and Sonographic Characteristics of Polycystic Ovary Syndrome (PCOS): Comparison between Nonobese and Obese Adolescents *J Clin Endocrinol Metab* 88: 4682-4688.
18. Weiss R, Dziura J, Bergert TS, et al, 2004 Obesity and the metabolic syndrome in children and adolescence. *N Engl J Med* 350: 2362-2374.
19. Cole T, Bellizzi M, Flegal K, 2000 Dietz W Establishing a standard definition for child overweight and obesity worldwide: international survey *BMJ* 320: 1240.
20. Ogden C, Flegal K, Carroll M, Johnson C, 2002 Prevalence and trends in overweight among US children and adolescents, 1999-2000. *JAMA* 288: 1728-1732.
21. Jehn M, Gittelsohn J, Treuth M, Caballero B, 2006 Prevalence of Overweight among Baltimore City Schoolchildren and its Associations with Nutrition and Physical Activity

- Obesity 14: 989-993.
22. Hansen B, 1999 The metabolic syndrome X. *Ann NY Acad Sci* 892: 1-24.
 23. Goodman E, Daniels SR, Morrison JA, Huang B, Dolan LM, 2004 Contrasting prevalence of and demographic disparities in the World Health Organization and National Cholesterol Education Program Adult Treatment Panel III definitions of metabolic syndrome among adolescents. *J Pediatr* 145: 445-451.
 24. Goodman E, Daniels S, Meigs J, Dolan L, 2007 Instability in the Diagnosis of Metabolic Syndrome in Adolescents. *115: 2316-2322.*
 25. Coviello A, Legro R, Dunaif A, 2006 Adolescent Girls with Polycystic Ovary Syndrome Have an Increased Risk of the Metabolic Syndrome Associated with Increasing Androgen Levels Independent of Obesity and Insulin Resistance. *J Clin Endocrinol Metab* 91: 492-497.
 26. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH, 2003 Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988–1994. *Arch Pediatr Adolesc Med* 157: 821-827.
 27. de Ferranti SD, Gauvreau K, Ludwig DS, Neufeld EJ, Newburger JW, Rifai N, 2004 Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey. *Circulation* 110: 2494-2497.
 28. Young-Hyman D, Schlundt D, Herman L, DeLuca F, Counts D, 2001 Evaluation of the insulin resistance syndrome in 5-to-10-year old overweight/obese African-American children. *Diabetes Care* 24: 1359-1364.
 29. Masuzaki H, Paterson J, Shinyama H, et al, 2001 A transgenic model of visceral obesity and the metabolic syndrome. *Science* 294: 2166-2170.
 30. Ten S, Maclaren N, 2004 Insulin Resistance Syndrome in Children *J Clin Endocrinol Metab* 89: 2526-2539.
 31. Cruz ML, Weigensberg MJ, Huang TT, Ball G, Shaibi GQ, Goran MI, 2004 The metabolic syndrome in overweight Hispanic youth and the role of insulin sensitivity. *J Clin Endocrinol Metab* 89: 108-113.
 32. Lopez-Capape M, Alonso M, Colino E, Mustieles C, Corbaton J, Barrio R, 2006 Frequency of the metabolic syndrome in obese Spanish pediatric population. *Eur J Endocrinol* 155: 313-319.
 33. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R, 2002 Obesity and the polycystic ovary syndrome. *Int J Obes Relat Metab Disord* 26: 883-896.
 34. McCartney C, Prendergast K, Chhabra S, et al, 2006 The association of obesity and hyperandrogenemia during the pubertal transition in girls: obesity as a potential factor in the genesis of postpubertal hyperandrogenism. *J Clin Endocrinol Metab* 91: 1714-1722.
 35. Marshall J, 2006 Obesity in Adolescent Girls: Is Excess Androgen the Real Bad Actor? *J Clin Endocrinol Metab* 91: 393-395.
 36. Pasquali R, Pelusi C, Genghini S, Cacciari M, Gambineri A, 2003 Obesity and reproductive disorders in women. *Hum Reprod Update* 9: 359-372.
 37. Kershaw EE, Flier JS, 2004 Adipose tissue as an endocrine organ. *J Clin Endocrinol Metab* 89: 2548-2556.
 38. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC, 1999 The insulin-related ovarian regulatory system in health and disease. *Endocr Rev* 20: 535-582.
 39. Willis D, Watson H, Mason D, Galea R, Brincat M, Franks S, 1998 Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation. *J Clin Endocrinol Metab* 83: 3984-3991.
 40. Wabitsch M, Hauner H, Heinze E, et al, 1995 Body fat distribution and steroid hormone concentrations in obese adolescent girls before and after weight reduction. *J Clin Endocrinol Metab* 80: 3469-3475.
 41. Reinehr T, de Sousa G, Roth CL, Andler W, 2005 Androgens before and after weight loss in obese children. *J Clin Endocrinol Metab* 90: 5588-5595.
 42. Baillargeon JP, Iuorno MJ, Nestler JE, 2003 Insulin sensitizers for polycystic ovary syndrome. *Clin Obstet Gynecol* 46: 325-340.
 43. Lord JM, Flight IH, Norman RJ, 2003 Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, d-chiro-inositol) for polycystic ovary syndrome. *Cochrane Database Syst Rev*: CD003053
 44. Marshall JC, Eagleson CA, 1999 Neuroendocrine aspects of polycystic ovary syndrome. *Endocrinol Metab Clin North Am* 28: 295-324.
 45. Apter D, Butzow T, Laughlin GA, Yen SS, 1994 Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovarian syndrome. *J Clin Endocrinol Metab* 79: 119-125.
 46. Venturoli S, Porcu E, Fabbri R, et al, 1992 Longitudinal evaluation of the different gonadotropin pulsatile patterns in anovulatory cycles of young girls. *J Clin Endocrinol Metab* 74: 836-841.
 47. Garcia-Rudaz MC, Ropelato MG, Escobar ME, Veldhuis JD, Barontini M, 1998 Augmented frequency and mass of LH discharged per burst are accompanied by marked disorderliness of LH secretion in adolescents with polycystic ovary syndrome. *Eur J Endocrinol* 139: 621-630.
 48. Veldhuis JD, Pincus SM, Garcia-Rudaz MC, Ropelato MG, Escobar ME, Barontini M, 2001 Disruption of the joint synchrony of luteinizing hormone, testosterone, and androstenedione secretion in adolescents with polycystic ovarian syndrome. *J Clin Endocrinol Metab* 86: 72-79.
 49. Daniels TL, Berga SL, 1997 Resistance of gonadotropin releasing hormone drive to sex steroid-induced suppression in hyperandrogenic anovulation. *J Clin Endocrinol Metab* 82: 4179-4183.
 50. Pastor CL, Griffin-Korf ML, Aloi JA, Evans WS, Marshall JC, 1998 Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse

- generator to inhibition by estradiol and progesterone. *J Clin Endocrinol Metab* 83: 582-590.
51. Chhabra S, McCartney CR, Yoo RY, Eagleson CA, Chang RJ, Marshall JC, 2005 Progesterone inhibition of the hypothalamic gonadotropin-releasing hormone pulse generator: evidence for varied effects in hyperandrogenic adolescent girls. *J Clin Endocrinol Metab* 90: 2810-2815.
 52. Eagleson CA, Gingrich MB, Pastor CL, et al, 2000 Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. *J Clin Endocrinol Metab* 85: 4047-4052.
 53. Pasquali R, 2006 Obesity and androgens: facts and perspectives *Fertil Steril* 85: 1319-1340.
 54. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE, 2004 Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 90: 1929-1935.
 55. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L, 2003 Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. *Metabolism* 52: 908-915.
 56. Arslanian SA, Lewy VD, Danadian K, 2001 Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and β -cell dysfunction and risk of cardiovascular disease. *J Clin Endocrinol Metab* 86: 66-71.
 57. Lewy VD, Danadian K, Witchel SF, Arslanian S 2001 Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. *J Pediatr* 138: 38-44.
 58. Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A, 2002 Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. *J Clin Endocrinol Metab* 87: 1017-1023.
 59. Gambineri A, Pelusi C, Genghini S, et al, 2004 Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. *Clin Endocrinol (Oxf)* 60: 241-249.
 60. Ibanez L, De Zegher F, 2003 Flutamide-metformin therapy to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism: effects in adolescents and in women on third-generation oral contraception. *J Clin Endocrinol Metab* 88: 4720-4724.
 61. Ibanez L, Valls C, Ferrer A, Ong K, Dunger DB, De Zegher F, 2002 Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation. *J Clin Endocrinol Metab* 87: 2870-2874.
 62. Dieudonne MN, Pecquery R, Boumediene A, Leneuve MC, Giudicelli Y, 1998 Androgen receptors in human preadipocytes and adipocytes: regional specificities and regulation by sex steroids. *Am J Physiol* 274: C1645-C1652.
 63. Wajchenberg BL, 2000 Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. *Endocr Rev* 21: 697-738.
 64. Leibel N, Baumann E, Kocherginsky M, Rosenfield R, 2006 Relationship of Adolescent Polycystic Ovary Syndrome to Parental Metabolic Syndrome. *J Clin Endocrinol Metab* 91: 1275-1283.
 65. Rosenfield R, 2007 Identifying Children at Risk for Polycystic Ovary Syndrome. *J Clin Endocrinol Metab* 92: 787-796.
 66. Diamanti Kandarakis E, Kandarakis H, Legro R, 2006 The Role of Genes and Environment in the Etiology of PCOS. *Endocrine* 30: 19-26.
 67. Abbott DH, Barnett DK, Bruns CM, Dumesic DA, 2005 Androgen excess fetal programming of female reproduction: a developmental etiology for polycystic ovary syndrome? *Hum Reprod Update* 11: 357-374.
 68. Monteiro PO, Victora CG, 2005 Rapid growth in infancy and childhood and obesity in later life—a systematic review. *Obes Rev* 6: 143-154.
 69. Eriksson JG, Forsen T, Tuomilehto J, Jaddoe VW, Osmond C, Barker DJ, 2002 Effects of size at birth and childhood growth on the insulin resistance syndrome in elderly individuals. *Diabetologia* 45: 342-348.
 70. Phenekos C, 2001 Influence of fetal body weight on metabolic complications in adult life: review of the evidence. *J Pediatr Endocrinol Metab* 14: 1361-1363.
 71. Ong KK, Ahmed ML, Emmett PM, Preece MA, Dunger DB, the ALSPAC Study Team, 2000 Association between postnatal catch-up growth and obesity in childhood: prospective cohort study. *BMJ* 320: 967-971.
 72. Stettler N, Stallings VA, Troxel AB, et al, 2005 Weight gain in the first week of life and overweight in adulthood: a cohort study of European American subjects fed infant formula. *Circulation* 111: 1897-1903.
 73. Soto N, Bazaes RA, Pena V, et al, 2003 Insulin sensitivity and secretion are related to catch-up growth in small-for-gestational-age infants at age 1 year: results from a prospective cohort. *J Clin Endocrinol Metab* 88: 3645-3650.
 74. Mericq V, Ong KK, Bazaes R, et al, 2005 Longitudinal changes in insulin sensitivity and secretion from birth to age three years in small- and appropriate-for-gestational-age children. *Diabetologia* 48: 2609-2614.
 75. Ong KK, Kratzsch J, Kiess W, Dunger DB, the ALSPAC Study Team, 2002 Circulating IGF-I levels in childhood are related to both current body composition and early postnatal growth rate. *J Clin Endocrinol Metab* 87: 1041-1044.
 76. Bhargava SK, Sachdev HS, Fall CH, et al, 2004 Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood. *N Engl J Med* 350: 865-875.
 77. Barker DJ, Osmond C, Forsen TJ, Kajantie E, Eriksson JG, 2005 Trajectories of growth among children who have coronary events as adults. *N Engl J Med* 353: 1802-1809.
 78. Ekelund U, Ong K, Linne Y, et al, 2006 Upward weight

- centile crossing in infancy and early childhood independently predict fat mass in young adults: the Stockholm Weight Development Study (SWEDES). *Am J Clin Nutr* 83: 324-330.
79. Ibanez L, Ong K, Dunger D, de Zegher F, 2006 Early Development of Adiposity and Insulin Resistance after Catch-Up Weight Gain in Small-for-Gestational-Age Children. *J Clin Endocrinol Metabol* 91: 2153-2158.
 80. Ozanne SE, Jensen CB, Tingey KJ, Storgaard H, Madsbad S, Vaag AA, 2005 Low birthweight is associated with specific changes in muscle insulin-signalling protein expression. *Diabetologia* 48: 547-552.
 81. Ibanez L, Potau N, Francois I, de Zegher F, 1998 Precocious pubarche, hyperinsulinism and ovarian hyperandrogenism in girls: relation to reduced fetal growth. *J Clin Endocrinol Metab* 83: 3558-3662.
 82. Ibanez L, Potau N, de Zegher F, 1999 Precocious pubarche, dyslipidemia and low IGFBP-1 in girls: relation to reduced prenatal growth. *Pediatr Res* 46: 320-322
 83. Ibanez L, Ong K, de Zegher F, Marcos MV, del Rio L, Dunger D, 2003 Fat distribution in non-obese girls with and without precocious pubarche: central adiposity related to insulinemia and androgenemia from pre-puberty to postmenarche. *Clin Endocrinol (Oxf)* 58: 372-379.
 84. Ibanez L, Jimenez R, de Zegher F, 2006 Early puberty-menarche after precocious pubarche: relation to prenatal growth. *Pediatrics* 117: 1171-1172.
 85. Ibanez L, Valls C, Potau N, Marcos MV, de Zegher F, 2001 Polycystic ovary syndrome after precocious pubarche: ontogeny of the low birthweight effect. *Clin Endocrinol (Oxf)* 55: 667-672.
 86. Ibanez L, Potau N, Virdis R, et al, 1993 Postpubertal outcome in girls diagnosed of premature pubarche during childhood: increased frequency of functional ovarian hyperandrogenism. *J Clin Endocrinol Metab* 76: 1599-1603.
 87. Ibanez L, de Zegher F, Potau N, 1999 Anovulation after precocious pubarche: early markers and time course in adolescence. *J Clin Endocrinol Metab* 84: 2691-2695.
 88. Ghirri P, Bernardini M, Vuerich M, et al, 2001 Adrenarche, pubertal development, age at menarche and final height of full-term, born small for gestational age (SGA) girls. *Gynecol Endocrinol* 15: 91-97.
 89. Ibanez L, Ferrer A, Ong K, Amin R, Dunger D, de Zegher F, 2004 Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome. *J Pediatr* 144: 23-29.
 90. Ibanez L, Valls C, Marcos MV, Ong K, Dunger DB, de Zegher F, 2004 Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: effects of prepubertal initiation and postpubertal discontinuation of metformin treatment. *J Clin Endocrinol Metab* 89: 4331-4337.
 91. Ibanez L, Valls C, Potau N, Marcos MV, de Zegher F, 2000 Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. *J Clin Endocrinol Metab* 85: 3526-3530.
 92. Ibanez L, Valls C, Ferrer A, Marcos MV, Rodriguez-Hierro F, de Zegher F, 2001 Sensitization to insulin induces ovulation in non-obese adolescents with anovulatory hyperandrogenism. *J Clin Endocrinol Metab* 86: 3595-3598.